Is IMNN or ALGS more profitable?

Imunon has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Imunon N/A -341.23% -153.79% Aligos Therapeutics -1,919.68% -139.47% -90.88%

Does the media refer more to IMNN or ALGS?

In the previous week, Aligos Therapeutics had 2 more articles in the media than Imunon. MarketBeat recorded 5 mentions for Aligos Therapeutics and 3 mentions for Imunon. Aligos Therapeutics' average media sentiment score of 0.15 beat Imunon's score of -0.04 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Imunon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aligos Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, IMNN or BRNS?

Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Imunon N/A N/A -$14.49M -$5.16 N/A Barinthus Biotherapeutics N/A N/A -$66.43M -$1.29 N/A

Is IMNN or BRNS more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Imunon N/A -341.23% -153.79% Barinthus Biotherapeutics N/A -63.83% -48.77%

Which has preferable earnings & valuation, EVAX or IMNN?

Evaxion A/S has higher revenue and earnings than Imunon. Evaxion A/S is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evaxion A/S $7.53M 3.32 -$7.71M -$1.47 N/A Imunon N/A N/A -$14.49M -$5.16 N/A

Is EVAX or IMNN more profitable?

Evaxion A/S's return on equity of -73.56% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% Imunon N/A -341.23% -153.79%

Do analysts recommend TXMD or IMNN?

Imunon has a consensus target price of $10.00, suggesting a potential upside of 532.91%. Given Imunon's stronger consensus rating and higher probable upside, analysts clearly believe Imunon is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Imunon 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TXMD or IMNN more profitable?

TherapeuticsMD has a net margin of 5.34% compared to Imunon's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets TherapeuticsMD 5.34% 0.32% 0.23% Imunon N/A -341.23% -153.79%

Which has better earnings & valuation, IMNN or TVRD?

Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Imunon N/A N/A -$14.49M -$5.16 N/A Tvardi Therapeutics N/A N/A -$18.21M -$3.10 N/A

Is IMNN or TVRD more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Imunon N/A -341.23% -153.79% Tvardi Therapeutics N/A -64.17% -43.90%

Does the media favor IMNN or TVRD?

In the previous week, Imunon had 2 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 3 mentions for Imunon and 1 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.16 beat Imunon's score of -0.04 indicating that Tvardi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Imunon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Imunon (IMNN) Competitors

$1.58 -0.01 (-0.63%)

As of 03:44 PM Eastern

Compare

IMNN vs. ALGS, BRNS, EVAX, TXMD, and TVRD

Should you buy Imunon stock or one of its competitors? MarketBeat compares Imunon with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Imunon include Aligos Therapeutics (ALGS), Barinthus Biotherapeutics (BRNS), Evaxion A/S (EVAX), TherapeuticsMD (TXMD), and Tvardi Therapeutics (TVRD).

How does Imunon compare to Aligos Therapeutics?

Imunon (NASDAQ:IMNN) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

In the previous week, Aligos Therapeutics had 2 more articles in the media than Imunon. MarketBeat recorded 5 mentions for Aligos Therapeutics and 3 mentions for Imunon. Aligos Therapeutics' average media sentiment score of 0.15 beat Imunon's score of -0.04 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aligos Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Imunon presently has a consensus price target of $10.00, suggesting a potential upside of 532.91%. Aligos Therapeutics has a consensus price target of $38.50, suggesting a potential upside of 605.90%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Imunon has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-341.23%	-153.79%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

4.5% of Imunon shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 2.8% of Imunon shares are held by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Imunon has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market.

Imunon has higher earnings, but lower revenue than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A
Aligos Therapeutics	$4.71M	7.17	-$24.19M	-$8.69	N/A

Summary

Aligos Therapeutics beats Imunon on 12 of the 16 factors compared between the two stocks.

How does Imunon compare to Barinthus Biotherapeutics?

Imunon (NASDAQ:IMNN) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, Imunon had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 3 mentions for Imunon and 1 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 0.00 beat Imunon's score of -0.04 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Imunon	Neutral
Barinthus Biotherapeutics	Neutral

4.5% of Imunon shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 2.8% of Imunon shares are held by company insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Imunon presently has a consensus price target of $10.00, suggesting a potential upside of 532.91%. Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 593.24%. Given Barinthus Biotherapeutics' higher probable upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.29	N/A

Barinthus Biotherapeutics' return on equity of -63.83% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-341.23%	-153.79%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Imunon has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market.

Summary

Barinthus Biotherapeutics beats Imunon on 7 of the 11 factors compared between the two stocks.

How does Imunon compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Evaxion A/S currently has a consensus target price of $11.00, suggesting a potential upside of 267.28%. Imunon has a consensus target price of $10.00, suggesting a potential upside of 532.91%. Given Imunon's higher probable upside, analysts plainly believe Imunon is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Evaxion A/S has higher revenue and earnings than Imunon. Evaxion A/S is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.32	-$7.71M	-$1.47	N/A
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A

Evaxion A/S has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Imunon has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market.

In the previous week, Imunon had 3 more articles in the media than Evaxion A/S. MarketBeat recorded 3 mentions for Imunon and 0 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 0.00 beat Imunon's score of -0.04 indicating that Evaxion A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Evaxion A/S	Neutral
Imunon	Neutral

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 2.8% of Imunon shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Evaxion A/S's return on equity of -73.56% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Imunon	N/A	-341.23%	-153.79%

Summary

Evaxion A/S beats Imunon on 10 of the 14 factors compared between the two stocks.

How does Imunon compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

TherapeuticsMD has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Imunon has a beta of 1.97, meaning that its stock price is 97% more volatile than the broader market.

TherapeuticsMD has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.01	-$570K	$0.06	34.83
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A

In the previous week, Imunon had 3 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for Imunon and 0 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.00 beat Imunon's score of -0.04 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Imunon	Neutral

Imunon has a consensus target price of $10.00, suggesting a potential upside of 532.91%. Given Imunon's stronger consensus rating and higher probable upside, analysts clearly believe Imunon is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

TherapeuticsMD has a net margin of 5.34% compared to Imunon's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Imunon	N/A	-341.23%	-153.79%

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 2.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

TherapeuticsMD beats Imunon on 9 of the 15 factors compared between the two stocks.

How does Imunon compare to Tvardi Therapeutics?

Imunon (NASDAQ:IMNN) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Tvardi Therapeutics' return on equity of -64.17% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-341.23%	-153.79%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

4.5% of Imunon shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 2.8% of Imunon shares are held by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Imunon has a beta of 1.97, suggesting that its stock price is 97% more volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A
Tvardi Therapeutics	N/A	N/A	-$18.21M	-$3.10	N/A

In the previous week, Imunon had 2 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 3 mentions for Imunon and 1 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.16 beat Imunon's score of -0.04 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Imunon presently has a consensus target price of $10.00, indicating a potential upside of 532.91%. Tvardi Therapeutics has a consensus target price of $18.00, indicating a potential upside of 867.74%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tvardi Therapeutics is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Tvardi Therapeutics beats Imunon on 10 of the 14 factors compared between the two stocks.

Get Imunon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNN vs. The Competition

Export

Metric	Imunon	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.64M	$3.60B	$6.91B	$12.84B
Dividend Yield	N/A	3.77%	2.60%	9.78%
P/E Ratio	-0.31	7.66	281.10	25.44
Price / Sales	N/A	1,199.86	571.60	79.78
Price / Cash	N/A	103.01	71.79	50.79
Price / Book	0.69	16.97	12.85	6.07
Net Income	-$14.49M	-$12.50M	$3.49B	$348.34M
7 Day Performance	-1.25%	2.55%	2.48%	3.07%
1 Month Performance	-20.20%	-4.87%	-2.81%	-3.04%
1 Year Performance	-80.78%	52.93%	75.60%	20.78%

Imunon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMNN Imunon	3.3482 of 5 stars	$1.58 -0.6%	$10.00 +532.9%	-81.8%	$6.64M	N/A	N/A	30	Upcoming Earnings Gap Up
ALGS Aligos Therapeutics	3.3846 of 5 stars	$4.25 +4.2%	$38.50 +805.9%	-40.1%	$25.25M	$2.19M	N/A	90	News Coverage Earnings Report Gap Down
BRNS Barinthus Biotherapeutics	2.298 of 5 stars	$0.59 -2.5%	$4.00 +582.6%	-57.5%	$24.55M	$14.97M	N/A	107	News Coverage Earnings Report
EVAX Evaxion A/S	2.6943 of 5 stars	$2.80 -3.1%	$11.00 +292.9%	+11.2%	$24.10M	$7.53M	N/A	60	Upcoming Earnings
TXMD TherapeuticsMD	1.3016 of 5 stars	$2.06 -0.5%	N/A	+88.2%	$23.96M	$3.02M	34.33	420

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNN) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Imunon (IMNN) Competitors

IMNN vs. ALGS, BRNS, EVAX, TXMD, and TVRD

How does Imunon compare to Aligos Therapeutics?

Summary

How does Imunon compare to Barinthus Biotherapeutics?

Summary

How does Imunon compare to Evaxion A/S?

Summary

How does Imunon compare to TherapeuticsMD?

Summary

How does Imunon compare to Tvardi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNN vs. The Competition

Imunon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Imunon (IMNN) Competitors

IMNN vs. ALGS, BRNS, EVAX, TXMD, and TVRD

How does Imunon compare to Aligos Therapeutics?

Does the media refer more to IMNN or ALGS?

Do analysts rate IMNN or ALGS?

Is IMNN or ALGS more profitable?

Do institutionals & insiders have more ownership in IMNN or ALGS?

Which has more risk & volatility, IMNN or ALGS?

Which has better earnings and valuation, IMNN or ALGS?

Summary

How does Imunon compare to Barinthus Biotherapeutics?

Does the media refer more to IMNN or BRNS?

Do insiders and institutionals have more ownership in IMNN or BRNS?

Do analysts rate IMNN or BRNS?

Which has stronger earnings & valuation, IMNN or BRNS?

Is IMNN or BRNS more profitable?

Which has more volatility and risk, IMNN or BRNS?

Summary

How does Imunon compare to Evaxion A/S?

Do analysts recommend EVAX or IMNN?

Which has preferable earnings & valuation, EVAX or IMNN?

Which has more volatility and risk, EVAX or IMNN?

Does the media prefer EVAX or IMNN?

Do institutionals & insiders have more ownership in EVAX or IMNN?

Is EVAX or IMNN more profitable?

Summary

How does Imunon compare to TherapeuticsMD?

Which has more volatility and risk, TXMD or IMNN?

Which has better earnings and valuation, TXMD or IMNN?

Does the media refer more to TXMD or IMNN?

Do analysts recommend TXMD or IMNN?

Is TXMD or IMNN more profitable?

Do insiders & institutionals have more ownership in TXMD or IMNN?

Summary

How does Imunon compare to Tvardi Therapeutics?

Is IMNN or TVRD more profitable?

Do institutionals & insiders believe in IMNN or TVRD?

Which has more risk and volatility, IMNN or TVRD?

Which has better earnings & valuation, IMNN or TVRD?

Does the media favor IMNN or TVRD?

Do analysts prefer IMNN or TVRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNN vs. The Competition

Imunon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools